<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151862">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123083</url>
  </required_header>
  <id_info>
    <org_study_id>115494</org_study_id>
    <secondary_id>TRX4018</secondary_id>
    <nct_id>NCT01123083</nct_id>
  </id_info>
  <brief_title>Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2</brief_title>
  <acronym>DEFEND-2</acronym>
  <official_title>DEFEND 2: Durable-Response Therapy Evaluation ForEarly- or New-Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective
      is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in
      insulin secretion as compared with placebo. Insulin secretion will be assessed using mixed
      meal-stimulated C-peptide.

      Subjects will be assigned to receive either otelixizumab or placebo at a ratio of 2:1 (2/3
      otelixizumab, 1/3 placebo). These study agents will be administered as an addition to
      insulin, diet, and other standard of care treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The following visits are required:

        -  Screening Visits: 2 to 3 appointments will be conducted to determine eligibility. At 2
           of these visits participants will drink a liquid meal and have blood tests done over
           the post-meal period. Participants will also be required to wear a continuous glucose
           monitor for a short period of time.

        -  Dosing Visits: 8 outpatient visits on consecutive days, each lasting about 2-4 hours.

        -  Follow-up Visits: weekly for the first month, then every 2 weeks for 3 months, followed
           by monthly visits through 1 year. There will be 3 visits in the second year.

        -  The total duration of the study is 2 years.

        -  Glucose test strips and glucose monitors will be provided to participants for the
           duration of the study. Frequent glycemic monitoring will occur through lab testing and
           blood glucose self-monitoring to help facilitate tight glycemic control in all
           subjects. Subjects will be asked to intermittently record their insulin doses using a
           telephone or web based system and continuous glucose monitoring will be performed every
           6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of C-peptide (a protein that shows how much insulin the body is producing) during a mixed meal stimulation test.</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average daily insulin use, HbA1c (a measurement of blood glucose control), and incidence of abnormal blood glucose levels.</measure>
    <time_frame>at Week 12, Months 6, 12, 18, and 24</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">179</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>otelixizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>otelixizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Otelixizumab</intervention_name>
    <description>infusion</description>
    <arm_group_label>otelixizumab</arm_group_label>
    <other_name>ChAglyCD3</other_name>
    <other_name>TRX4</other_name>
    <other_name>monoclonal antibody</other_name>
    <other_name>anti-CD3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Infusion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 12-17

          -  Diagnosis of diabetes mellitus, consistent with ADA criteria

          -  No more than 90 days between diagnosis and administration of study compounds

          -  Requires insulin for type 1 diabetes mellitus, or has required insulin at some time
             between diagnosis and administration of study compounds. In Canada, has to be using
             insulin at the time of dosing.

          -  Stimulated C-peptide level greater than 0.20 nmol/L and less than or equal to 3.50
             nmol/L

          -  Positive for one or more of the autoantibodies typically associated with T1DM:
             antibody to glutamic acid decarboxylase (anti‑GAD); antibody to protein tyrosine
             phosphatase-like protein (anti‑IA‑2); zinc transporter autoantibodies (ZNT8); insulin
             autoantibodies (IAA). A subject who is positive for insulin autoantibodies (IAA) and
             negative for the other autoantibodies will only be eligible if the subject has used
             insulin for less than 7 days total.

        Exclusion Criteria:

        •Other, significant medical conditions based on the study doctor's evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.defendagainstdiabetes.com</url>
    <description>Website containing information regarding the DEFEND-2 trial</description>
  </link>
  <reference>
    <citation>Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G, Gorus F, Goldman M, Walter M, Candon S, Schandene L, Crenier L, De Block C, Seigneurin JM, De Pauw P, Pierard D, Weets I, Rebello P, Bird P, Berrie E, Frewin M, Waldmann H, Bach JF, Pipeleers D, Chatenoud L. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005 Jun 23;352(25):2598-608.</citation>
    <PMID>15972866</PMID>
  </reference>
  <reference>
    <citation>Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, Vandemeulebroucke E, Van de Velde U, Crenier L, De Block C, Candon S, Waldmann H, Ziegler AG, Chatenoud L, Pipeleers D. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia. 2010 Apr;53(4):614-23. Epub 2010 Jan 14.</citation>
    <PMID>20225393</PMID>
  </reference>
  <reference>
    <citation>You S, Candon S, Kuhn C, Bach JF, Chatenoud L. CD3 antibodies as unique tools to restore self-tolerance in established autoimmunity their mode of action and clinical application in type 1 diabetes. Adv Immunol. 2008;100:13-37. doi: 10.1016/S0065-2776(08)00802-X. Review.</citation>
    <PMID>19111162</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 21, 2016</lastchanged_date>
  <firstreceived_date>May 11, 2010</firstreceived_date>
  <firstreceived_results_disposition_date>November 15, 2012</firstreceived_results_disposition_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>new onset type 1 diabetes</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>T1DM</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115494</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
